B lymphocyte-typing for prediction of clinical response to rituximab
Open Access
- 1 January 2012
- journal article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 14 (4), R161
- https://doi.org/10.1186/ar3901
Abstract
The prediction of therapeutic response to rituximab in rheumatoid arthritis is desirable. We evaluated whether analysis of B lymphocyte subsets by flow cytometry would be useful to identify non-responders to rituximab ahead of time. Fifty-two patients with active rheumatoid arthritis despite therapy with TNF-inhibitors were included in the national rituximab registry. DAS28 was determined before and 24 weeks after rituximab application. B cell subsets were analyzed by high-sensitive flow cytometry before and 2 weeks after rituximab administration. Complete depletion of B cells was defined as CD19-values below 0.0001 x109 cells/liter. At 6 months 19 patients had a good (37%), 23 a moderate (44%) and 10 (19%) had no EULAR-response. The extent of B lymphocyte depletion in peripheral blood did not predict the success of rituximab therapy. Incomplete depletion was found at almost the same frequency in EULAR responders and non-responders. In comparison to healthy controls, non-responders had elevated baseline CD95+ pre-switch B cells, whereas responders had a lower frequency of plasmablasts. The baseline enumeration of B lymphocyte subsets is still of limited clinical value for the prediction of response to anti-CD20 therapy. However, differences at the level of CD95+ pre switch B cells or plasmablasts were noticed with regard to treatment response. The criterion of complete depletion of peripheral B cells after rituximab administration did not predict the success of this therapy in rheumatoid arthritis.This publication has 29 references indexed in Scilit:
- Advances in rheumatology: new targeted therapeuticsArthritis Research & Therapy, 2011
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010Annals Of The Rheumatic Diseases, 2011
- Reduced-dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletionArthritis & Rheumatism, 2010
- Management of nonresponse to rituximab in rheumatoid arthritis: Predictors and outcome of re‐treatmentArthritis & Rheumatism, 2010
- Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritisArthritis Research & Therapy, 2009
- Class-switched B cells display response to therapeutic B cell depletion in rheumatoid arthritisArthritis Research & Therapy, 2009
- Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritisArthritis & Rheumatism, 2008
- Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B‐Cell Levels Do Not Correlate With Clinical ResponseThe Journal of Clinical Pharmacology, 2007
- Regeneration of B cell subsets after transient B cell depletion using anti‐CD20 antibodies in rheumatoid arthritisArthritis & Rheumatism, 2006
- Identification and characterization of circulating human transitional B cellsBlood, 2005